Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2017 from OUS - Section for Preventive Cardiology
22 publications found
Cardiovascular disease and diabetes in patients with African or Asian background
Tidsskr Nor Laegeforen, 137 (22)
DOI 10.4045/tidsskr.16.0680, PubMed 29181932
Cardiovascular disease and diabetes by African or Asian background
Tidsskr. Nor. Laegeforen., 137 (22), 1790-1794
Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies
Int J Epidemiol, 46 (3), 1029-1056
DOI 10.1093/ije/dyw319, PubMed 28338764
Physical activity and the risk of preterm birth: a systematic review and meta-analysis of epidemiological studies
BJOG, 124 (12), 1816-1826
DOI 10.1111/1471-0528.14672, PubMed 28374930
Body mass index and physical activity and the risk of diverticular disease: a systematic review and meta-analysis of prospective studies
Eur J Nutr, 56 (8), 2423-2438
DOI 10.1007/s00394-017-1443-x, PubMed 28393286
Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - A systematic review and dose-response meta-analysis of prospective studies
Nutr Metab Cardiovasc Dis, 27 (6), 504-517
DOI 10.1016/j.numecd.2017.04.004, PubMed 28552551
Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies
Eur J Epidemiol, 32 (3), 181-192
DOI 10.1007/s10654-017-0232-4, PubMed 28194602
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Circulation, 137 (4), 338-350
DOI 10.1161/CIRCULATIONAHA.117.032235, PubMed 29133605
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Rev Esp Cardiol (Engl Ed), 70 (2), 115
DOI 10.1016/j.rec.2017.01.002, PubMed 29389351
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
JAMA Cardiol, 2 (10), 1069-1078
DOI 10.1001/jamacardio.2017.2762, PubMed 28832867
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
JAMA Cardiol, 2 (12), 1385-1391
DOI 10.1001/jamacardio.2017.3944, PubMed 29117276
Cognitive Function in a Randomized Trial of Evolocumab
N Engl J Med, 377 (7), 633-643
DOI 10.1056/NEJMoa1701131, PubMed 28813214
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial
Clin Cardiol, 40 (2), 59-65
DOI 10.1002/clc.22678, PubMed 28207168
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Lancet, 390 (10106), 1962-1971
DOI 10.1016/S0140-6736(17)32290-0, PubMed 28859947
Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study)
Am J Cardiol, 121 (6), 739-745
DOI 10.1016/j.amjcard.2017.12.011, PubMed 29361285
New guidelines for the prevention of cardiovascular disease
Tidsskr. Nor. Laegeforen., 137 (16), 1164-1168
The PED-t trial protocol: The effect of physical exercise -and dietary therapy compared with cognitive behavior therapy in treatment of bulimia nervosa and binge eating disorder
BMC Psychiatry, 17 (1), 180
DOI 10.1186/s12888-017-1312-4, PubMed 28494809
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
N Engl J Med, 376 (18), 1713-1722
DOI 10.1056/NEJMoa1615664, PubMed 28304224
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Lancet Diabetes Endocrinol, 5 (12), 941-950
DOI 10.1016/S2213-8587(17)30313-3, PubMed 28927706
A Missense Variant in PLEC Increases Risk of Atrial Fibrillation
J Am Coll Cardiol, 70 (17), 2157-2168
DOI 10.1016/j.jacc.2017.09.005, PubMed 29050564
[Statin intolerance]
Tidsskr Nor Laegeforen, 137 (1), 36-38
DOI 10.4045/tidsskr.16.0646, PubMed 28073228
Statins for children with familial hypercholesterolemia
Cochrane Database Syst Rev, 7, CD006401
DOI 10.1002/14651858.CD006401.pub4, PubMed 28685504